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Objective: Iodine-123 metaiodobenzylguanidine (MIBG) cardiac scintigraphy has shown the potential to
discriminate dementia with Lewy bodies (DLB) from Alzheimer’s disease (AD). However, these studies
did not reflect clinical practice, as patients with ischemic heart disease, heart failure, diabetes mellitus, arterial
hypertension, and hyperlipidemia and patients treated with antidepressants like trazodone were excluded.
Methods: This study aimed to evaluate the use of MIBG cardiac scintigraphy to diagnose DLB in clinical
practice. Moreover, the potential diagnostic value of MIBG cardiac scintigraphy in patients with clini-
cally ambiguous dementia diagnosis (DLB versus AD) was tested. Eighty-five patients with a possible
clinical diagnosis of DLB entered the study. MIBG uptake was determined by calculating the heart-
to-mediastinum-uptake ratio (H/M).
Results:The average H/M ratio was 1.42±0.35. The number of core features for DLB and the H/M ratio
were negatively correlated (p=0.001; r=0.360). With an H/M ratio cutoff of 1.68 in 20 patients with
clinically ambiguous dementia diagnoses (DLB versus AD) at the moment of MIBG cardiac scintigra-
phy, 95% (19/20) of the patients were correctly classified as compared with clinical or definite diagnosis
at follow-up, with sensitivity and specificity values for diagnosing DLB of 100% (16/16) and 75% (3/4),
respectively. The H/M ratio was influenced only by age (p=0.046; r=0.217) and gender (p=0.024)
and not by any other variable studied.
Conclusions: The MIBG cardiac scintigraphy H/M ratio is a possible diagnostic biomarker for DLB in
routine clinical practice and might have an added diagnostic value in case of doubt between DLB and AD.
# 2014 The Authors. International Journal of Geriatric Psychiatry published by John Wiley & Sons, Ltd.
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Dementia with Lewy bodies (DLB) is the second most
common cause of neurodegenerative dementia in older
people after Alzheimer’s disease (AD). Given the overlap
in clinical symptoms between DLB and AD, differential
diagnosis is difficult (Merdes et al., 2003). Although the
cerebrospinal fluid (CSF) biomarkers Aβ1–42, T-tau and
P-tau181P have an added diagnostic value for differential
dementia diagnosis, concomitant amyloid pathology in
DLB limits the use of CSF Aβ1–42 for discriminating
DLB from AD (Slaets et al., 2013). However, discrim-
ination between DLB and AD is clinically relevant, as
there is a difference in pharmacological treatment
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options (e.g., severe adverse effects to antipsychotic
drugs in DLB patients). Moreover, an early and accu-
rate (differential) dementia diagnosis will become
more and more important once disease-modifying
drugs for AD or other neurodegenerative brain dis-
eases will become available, as these (potentially toxic)
drugs will probably be pathology specific.
Iodine-123 metaiodobenzylguanidine (MIBG)
cardiac scintigraphy has been proposed as a
method to differentiate between DLB and AD.
The uptake and storage in presynaptic vesicles of
MIBG is probably identical to norepinephrine
(Wieland et al., 1980). MIBG is released into the
synaptic cleft but is not metabolized. The de-
creased cardiac uptake of MIBG in DLB reflects
the postganglionic cardiac sympathetic denervation
(Orimo et al., 2005). Promising results have been
published, but these studies have been conducted
under very strict exclusion criteria (Yoshita et al.,
2001, Yoshita et al., 2006, Watanabe et al., 2001,
Oide et al., 2003, Hanyu et al., 2006, Wada-Isoe
et al., 2007). Indeed, patients with ischemic heart
disease, heart failure, thyroid disease, or diabetes
mellitus were excluded (Yoshita et al., 2001,
Yoshita et al., 2006, Watanabe et al., 2001, Oide
et al., 2003). Moreover, patients with arterial hy-
pertension or hyperlipidemia (Yoshita et al., 2001,
Yoshita et al., 2006) and patients on antidepressant
medication like trazodone or on antipsychotics like
haloperidol were excluded from these studies (Yoshita
et al., 2001, Yoshita et al., 2006, Watanabe et al.,
2001, Oide et al., 2003). As most patients with a cogni-
tive deterioration are older people having comorbidities
like arterial hypertension, diabetes mellitus, cardiovas-
cular disease, thyroid disease, or hyperlipidemia, these
studies do not reflect clinical practice.
This study aimed to evaluate the use of MIBG
cardiac scintigraphy to diagnose DLB in clinical
practice. Moreover, the potential diagnostic value
of MIBG cardiac scintigraphy in patients with clin-
ically ambiguous dementia (DLB versus AD) diag-
nosis was tested.
Methods
The study population consisted of patients visiting
the memory clinic between 2006 and 2013 and in
whom DLB was considered as a possible clinical di-
agnosis (n=85). For all patients, the presence of
core features and suggestive features for DLB, as de-
termined by McKeith et al. (McKeith et al., 2005),
were recorded. Relevant concomitant diseases and
conditions like diabetes mellitus, arterial hyperten-
sion, hyperlipidemia, ischemic heart disease, and
heart failure as well as pharmacological treatments
at the time of MIBG scanning were recorded.
Patients were injected with MIBG (2mCi), and
images were acquired 4 h after injection. The data
of 67 patients were acquired with a Philips XCT
scanner, whereas for 18 patients, the data were
acquired with a Varicam (GE) scanner, both with
a low-energy, high-resolution collimator. Both
cameras had similar hardware characteristics
(LEHR collimator, large field double-head cam-
era) and the same settings of acquisition parame-
ters (energy spectrum, pixel size, scan duration).
Thyroid blockage was acquired with potassium
perchlorate. MIBG uptake was determined by
calculating the heart-to-mediastinum-uptake (H/M)
ratio. By applying the H/M ratio, potential differences
due to the use of two different cameras were minimized.
All the scans were analyzed by the same nuclear medi-
cine physician (FVA) who drew the regions of interest
and evaluated the scans.
Patients were followed up at the memory clinic.
The physicians who clinically followed up the
patients were not blinded to the MIBG results at base-
line. At follow-up, the clinical diagnosis of probable
AD was made according to the National Institute of
Neurological and Communicative Disorders and
Stroke -Alzheimer’s Disease and Related Disorders
Association (NINCDS-ADRDA) criteria (McKhann
et al., 1984). Probable DLB was diagnosed accord-
ing to the criteria of McKeith et al. (McKeith
et al., 2005). In case consenting patients died, au-
topsy was performed in order to establish a definite
dementia diagnosis. For the neuropathological di-
agnosis of AD, the criteria of Braak and Braak
(1991) and Braak et al. (2006) were applied as de-
scribed earlier (Le Bastard et al., 2013).
Diagnostic accuracy of MIBG cardiac scintigra-
phy was tested as compared with the definite or
clinical dementia diagnosis at follow-up. A t-test
was used to evaluate the difference with regard to
the H/M ratio between patients with and without
diabetes mellitus, possibly interfering medication,
arterial hypertension, and hyperlipidemia. To exam-
ine the relationship between the H/M ratio and age,
the number of core and suggestive features of DLB,
a Pearson’s correlation coefficient was executed. A
significance level of <0.05 was considered signifi-
cant. Statistical analyses were performed using SPSS
20 (SPSS Inc., Chicago, USA).
This study was approved by the ethics committee of
the University of Antwerp, Antwerp, Belgium.
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Results
Data of 85 patients with a possible clinical diagnosis of
DLB were available for data analyses. The average age
of the population was 76±8years. The population
consisted of 52 males and 33 females. The average
MMSE score was 20±6 (n=84). Ten patients had di-
abetes mellitus type II, and 10 patients suffered from a
thyroid dysfunction. These conditions were treated in
all patients. Twenty-two patients were treated with
trazodone for diurnal rhythm disturbances, and two
patients were treated with haloperidol. Twenty-seven
patients presented with arterial hypertension, and 17
patients presented with hyperlipidemia. Nine patients
had ischemic heart disease, and three patients had
both heart failure and ischemic heart disease.
The H/M ratios for the population are represented in
Figure 1. The average H/M ratio was 1.42±0.35. The
H/M ratio was lower in males (1.35±0.37) when com-
pared with that in females (1.51±0.29) (p=0.024). The
H/M ratio was not significantly lower in patients treated
with trazodone (p=0.908). No significant difference
could be found in patients with diabetes mellitus type
II, arterial hypertension, heart failure/ischemic heart dis-
ease, hyperlipidemia, and thyroid dysfunction (p=0.171;
p=0.104; p=0.104; p=0.349; p=0.106). A significant
negative correlation was found between age and the
H/M ratio (p=0.046; r=0.217).
A negative correlation between the number of core
features for DLB and the H/M ratio (p=0.001;
r=0.360) was found (Figure 2). No significant cor-
relation was found between disease duration and the
H/M ratio (p=0.286) or between the number of sug-
gestive features and the H/M ratio (p=0.060).
The MIBG classification and the clinical or
definite dementia diagnosis at follow-up were
compared for patients with clinically ambiguous
diagnoses (AD or DLB) at baseline and either
one of the following: (i) clinical follow-up of more
than six months after MIBG cardiac scintigraphy
(n=19) or (ii) autopsy confirmation of the clinical
diagnosis (n=1) (Table 1). The clinical diagnosis
at last follow-up or the definite dementia diagnosis
was used to test the diagnostic accuracy of the
MIBG H/M ratio at baseline. The mean follow-up
term was 17± 14months (range: 6–57 months)
(Table 1). One patient had an autopsy-confirmed
diagnosis of AD (case no. 5, Table 1). His H/M ra-
tio was 1.76. This patient had Braak stage III–IV
for neurofibrillary tangles, and no Lewy bodies were
found. Based on the literature (Yoshita et al., 2006),
an H/M ratio cutoff of 1.68 was used for the classi-
fication of patients based on MIBG cardiac scintig-
raphy. Applying the H/M ratio cutoff of 1.68, 95%
(19/20) of the patients with clinically ambiguous di-
agnoses were correctly classified, with sensitivity
and specificity values of 100% (16/16) and 75%
(3/4), respectively, as compared with diagnosis at
follow-up.
Figure 1 H/M ratios for the total population. The average H/M ratio was 1.42 ± 0.35. The H/M ratio cutoff of 1.68 of Yoshita et al. (Yoshita et al.,
2006) to distinguish between AD and DLB is shown.
Figure 2 Correlation between number of core features of DLB and the
H/M ratio (p = 0.001; r =3.60).
866 S. Slaets et al.
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Discussion
Previous research has shown promising results for the use
of MIBG cardiac scintigraphy as a diagnostic tool to dis-
tinguish DLB from AD (Yoshita et al., 2001, Yoshita
et al., 2006,Watanabe et al., 2001, Oide et al., 2003, Hanyu
et al., 2006, Wada-Isoe et al., 2007) with sensitivity and
specificity values of 100% (Yoshita et al., 2006). However,
most studies included limited study populations, and
studies in Caucasian populations are sparse. Moreover,
in former studies, the populations consisted of patients
with a probable clinical diagnosis of AD or of DLB. Also,
patients with diabetes mellitus, arterial hypertension,
heart failure, cardiac ischemic heart disease, or hyperlipid-
emia were excluded from these studies as well as patients
under pharmacological treatment (like trazodone or hal-
operidol) that could influence MIBG uptake (Solanki
et al., 1992). In our study population, 62% of the patients
(53/85) would have been excluded if the exclusion criteria
of previously published papers were applied. Nevertheless,
in clinical practice, there often is diagnostic doubt be-
tween DLB and AD, given the overlap in clinical symp-
toms as well as an AD CSF biomarker profile that is
often encountered in DLB patients (Slaets et al., 2013).
In the current study, we wanted to evaluate the use of
MIBG cardiac scintigraphy for diagnosing DLB in clinical
practice, not excluding patients with diabetes mellitus, is-
chemic heart disease, heart failure, arterial hypertension,
or hyperlipidemia or patients treated withmedication that
could possibly influence MIBG uptake.
In the current study, a significant and negative correla-
tion was found between the number of core features of
DLB and the H/M ratio (p=0.001; r=0.360), suggest-
ing that decreased H/M ratios are intrinsically related to
the clinical features of DLB. Previous research from
Kobayashi et al. (Kobayashi et al., 2009) has also found
a relation between the H/M ratio and the clinical symp-
toms in DLB. In the latter study, a lower H/M ratio was
found in DLB patients with orthostatic hypotension when
compared with DLB patients without orthostatic hypo-
tension. Although we detected a correlation with the
number of core features, no correlation was found be-
tween the H/M ratio and disease duration, suggesting that
low H/M ratios can be found early in the disease course,
which is in accordance with several previous studies
(Fujishiro et al., 2012, Sakakibara et al., 2012, Estorch
et al., 2008).
Moreover, the potential diagnostic value of MIBG car-
diac scintigraphy in patients with clinically ambiguous de-
mentia (DLB versus AD) diagnoses was tested. Clinically
ambiguous diagnoses resulted from diagnostic doubt be-
tween DLB and AD following routine clinical diagnostic
workup. Applying the H/M ratio cutoff of 1.68 (Yoshita
et al., 2006), the sensitivity and specificity for a diagnosis
of DLB in this clinical population were 100% and 75%,
respectively (Figure 1). In the study of Yoshita et al.
(Yoshita et al., 2006) that examined the use of theH/M ra-
tio to distinguish between AD andDLB in however highly
selected populations, a sensitivity and specificity value of
100% was achieved (Yoshita et al., 2006).
In this study, a negative correlation was found between
age and H/M ratio (p=0.046; r=0.217). These results
are consistent with other studies and are suggestive of a re-
duced neuronal reuptake of norepinephrine with aging
(Sakata et al., 2009). The H/M ratio was also lower in
men (p=0.024). Differences in H/M ratios as a result of
gender and age could possibly lead to false-positive results.
Therefore, an age- and gender-correctedH/M ratio should
be considered to increase the diagnostic accuracy ofMIBG
cardiac scintigraphy.
In previous studies, patients with comorbidities that
might affect MIBG cardiac scintigraphy were excluded.
In our population that reflects clinical practice, cardiovas-
cular comorbidities and thyroid dysfunction had no signif-
icant effect on H/M ratios. In the present study, 22/85
patients were treated with trazodone at the moment of
MIBG cardiac scintigraphy. Although a decrease in H/M
ratio was theoretically to be expected due to the depletion
of storage vesicles by trazodone (Solanki et al., 1992), we
could not detect a difference in H/M ratios comparing pa-
tients treated with and without trazodone (p=0.908). This
finding is supported by previous in vitro research on rabbit
myocardium where no influence of trazodone could be
detected (Mayer et al., 2000).
Finally, a number of limitations need to be considered.
The sensitivity and specificity values calculated in this
study were based on a relatively small number of patients,
because only patients with possible clinical diagnoses of
DLB were included in this study, moreover resulting in
few patients with other (than DLB) neurodegenerative
brain disorders. The physicians who clinically followed
up the patients were not blinded to the MIBG results at
baseline. The H/M cutoff value that was used was based
on literature although it has been shown that the optimal
cutoff can vary between centers.
Further research through a large prospective, longitu-
dinal study is needed to confirm the diagnostic potential
of MIBG cardiac scintigraphy for DLB and to discrimi-
nate DLB from AD. Studies that contain patients with
autopsy-confirmed dementia diagnoses (both DLB and
other neurodegenerative dementias like AD) are espe-
cially needed to confirm the diagnostic potential of
MIBG cardiac scintigraphy for differential dementia di-
agnosis and to gain more insight into factors of potential
influence on theH/M ratio, like psychotropicmedication
and cardiovascular comorbidities.
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Conclusion
The MIBG cardiac scintigraphy H/M ratio is a possi-
ble diagnostic biomarker for DLB in routine clinical
practice and might have an added diagnostic value
in case of doubt between DLB and AD.
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• Given the overlap in clinical symptoms between
DLB and AD, differential diagnosis is difficult.
• MIBG cardiac scintigraphy H/M ratio is a possible
diagnostic biomarker for DLB.
• MIBG cardiac scintigraphy might have an added
diagnostic value in case of doubt between DLB
and AD.
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